|
US7989589B2
(en)
*
|
2002-09-20 |
2011-08-02 |
The Trustees Of The University Of Pennsylvania |
Compstatin analogs with improved activity
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
ES2390828T3
(es)
|
2005-11-28 |
2012-11-16 |
The Trustees Of The University Of Pennsylvania |
Análogos potentes de la compstatina
|
|
US8637325B2
(en)
*
|
2009-02-16 |
2014-01-28 |
University Of Wyoming |
Method and apparatus for pyrolysis-induced cleavage in peptides and proteins
|
|
CA2666843C
(en)
*
|
2006-10-20 |
2015-06-16 |
Celldex Therapeutics, Inc. |
Treatment of age-related macular degeneration and other diseases of the eye
|
|
EP2148691B1
(en)
*
|
2007-02-05 |
2015-05-20 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
|
|
JP2009003429A
(ja)
*
|
2007-05-18 |
2009-01-08 |
Panasonic Corp |
アクチュエータ
|
|
WO2008153963A1
(en)
*
|
2007-06-08 |
2008-12-18 |
The Trustees Of The University Of Pennsylvania |
Structure of compstatin-c3 complex and use for rational drug design
|
|
WO2009005651A2
(en)
|
2007-06-29 |
2009-01-08 |
The Trustees Of The University Of Pennsylvania |
Complement-mediated thrombophilic assay
|
|
CA2701470A1
(en)
*
|
2007-10-02 |
2009-04-09 |
Potentia Pharmaceuticals, Inc. |
Sustained delivery of compstatin analogs from gels
|
|
WO2009121065A2
(en)
*
|
2008-03-28 |
2009-10-01 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
WO2010039690A1
(en)
*
|
2008-09-30 |
2010-04-08 |
The Trustees Of The University Of Pennsylvania |
Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
|
|
CA2760839C
(en)
*
|
2009-05-01 |
2019-02-12 |
The Trustees Of The University Of Pennsylvania |
Modified compstatin with peptide backbone and c-terminal modifications
|
|
US20110104154A1
(en)
|
2009-10-30 |
2011-05-05 |
Alcon Research, Ltd. |
Single nucleotide polymorphisms and genes associated with age-related macular degeneration
|
|
WO2011106635A1
(en)
|
2010-02-25 |
2011-09-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of sepsis using complement inhibitors
|
|
US9421240B2
(en)
|
2010-06-22 |
2016-08-23 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
CA2813049A1
(en)
|
2010-09-23 |
2012-03-29 |
The Trustees Of The University Of Pennsylvania |
Modified compstatin with improved stability and binding properties
|
|
BR112013007442A2
(pt)
*
|
2010-09-28 |
2019-09-24 |
Amylin Pharmaceuticals Llc |
polipeptídeos construídos tendo duração de ação realçada
|
|
WO2012095519A1
(en)
|
2011-01-13 |
2012-07-19 |
Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie |
Potent inhibitors of complement activation
|
|
WO2012135624A1
(en)
|
2011-04-01 |
2012-10-04 |
The Trustees Of The University Of Pennsylvania |
Treatment of colon cancer using complement inhibitors
|
|
RU2653439C9
(ru)
|
2011-05-11 |
2018-10-16 |
Апеллис Фармасьютикалс, Инк. |
Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение
|
|
WO2012162215A1
(en)
|
2011-05-20 |
2012-11-29 |
The Trustees Of The University Of Pennsylvania |
Promotion of fracture healing using complement inhibitors
|
|
WO2012174055A1
(en)
|
2011-06-13 |
2012-12-20 |
The Trustees Of The University Of Pennsylvania |
Wound healing using complement inhibitors
|
|
CA2840270C
(en)
|
2011-06-22 |
2023-09-26 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
PL2753636T3
(pl)
*
|
2011-09-07 |
2020-05-18 |
The Trustees Of The University Of Pennsylvania |
Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
|
|
WO2014028861A1
(en)
*
|
2012-08-17 |
2014-02-20 |
Apellis Pharmaceuticals, Inc. |
Detection of high risk drusen
|
|
WO2014078734A2
(en)
*
|
2012-11-15 |
2014-05-22 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
US10035822B2
(en)
*
|
2012-11-15 |
2018-07-31 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
WO2014100407A1
(en)
*
|
2012-12-19 |
2014-06-26 |
The Regents Of The University Of California |
Compstatin analogs
|
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
WO2015089368A2
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
|
US10213476B2
(en)
|
2014-03-17 |
2019-02-26 |
The Trustees Of The University Of Pennsylvania |
Compstatin analogs with improved potency and pharmacokinetic properties
|
|
MX2017005454A
(es)
|
2014-12-23 |
2017-07-04 |
Multi Chem Group Llc |
Agentes depuradores de azufre a base de acrilato para usarse en actividades en pozos petroleros.
|
|
WO2017035409A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
|
|
WO2017035405A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of immune and inflammatory disorders
|
|
WO2017035401A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amide compounds for treatment of immune and inflammatory disorders
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
KR20180090785A
(ko)
|
2015-10-07 |
2018-08-13 |
아펠리스 파마슈티컬스 인코포레이티드 |
투여 요법
|
|
EP3526328A4
(en)
|
2016-10-17 |
2020-05-27 |
Apellis Pharmaceuticals, Inc. |
COMBINATION THERAPY FOR C3 INHIBITION
|
|
CA3053818A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
|
|
WO2018160891A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceutical, Inc. |
Pharmaceutical compounds for treatment of medical disorders
|
|
BR112019020955A2
(pt)
|
2017-04-07 |
2020-05-05 |
Apellis Pharmaceuticals, Inc. |
regimes de dosagem e composições e métodos relacionados
|
|
WO2019028284A1
(en)
|
2017-08-02 |
2019-02-07 |
Achillion Pharmaceuticals, Inc. |
THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA
|
|
CA3078971A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
|
JP2021507884A
(ja)
|
2017-12-15 |
2021-02-25 |
アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
投与レジメンならびに関連組成物および方法
|
|
BR112020017385A2
(pt)
|
2018-02-27 |
2020-12-15 |
Zp Spv 3 K/S |
Análogos de compstatina, métodos e seus usos médicos
|
|
HUE057693T2
(hu)
|
2018-04-06 |
2022-05-28 |
Univ Pennsylvania |
Fokozott oldhatóságú és javított farmakokinetikai tulajdonságú kompsztatin analógok
|
|
WO2020051538A1
(en)
|
2018-09-06 |
2020-03-12 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of complement factor d inhibitors
|
|
JP7443375B2
(ja)
|
2018-09-06 |
2024-03-05 |
アキリオン ファーマシューティカルズ， インコーポレーテッド |
医学的障害の治療のための大環状化合物
|
|
WO2020069024A1
(en)
|
2018-09-25 |
2020-04-02 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of complement factor d inhibitors
|
|
CN113195472A
(zh)
|
2018-12-17 |
2021-07-30 |
艾其林医药公司 |
用于治疗补体介导的病症的靶向给药
|
|
MX2021011507A
(es)
|
2019-03-22 |
2021-12-15 |
Achillion Pharmaceuticals Inc |
Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
|
|
US11510939B1
(en)
|
2019-04-19 |
2022-11-29 |
Apellis Pharmaceuticals, Inc. |
RNAs for complement inhibition
|
|
ES3049784T3
(en)
|
2019-08-27 |
2025-12-18 |
Zp Spv 3 K/S |
Compstatin analogues and their medical uses
|
|
CA3158320A1
(en)
|
2019-10-22 |
2021-04-29 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
|
JP2023515073A
(ja)
|
2020-02-20 |
2023-04-12 |
アキリオン ファーマシューティカルズ， インコーポレーテッド |
補体因子ｄ媒介障害の処置用のヘテロアリール化合物
|
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
MX2022013606A
(es)
|
2020-04-30 |
2023-01-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
|
|
KR20230009431A
(ko)
|
2020-05-12 |
2023-01-17 |
알렉시온 파마슈티칼스, 인코포레이티드 |
발작성 야간 혈색소뇨증의 치료를 위한 보체 인자 d 저해제를 단독으로 또는 항-c5 항체와 조합한 용도
|
|
JP2023538807A
(ja)
|
2020-07-16 |
2023-09-12 |
セッドぺー エスぺーヴェー ３ カー／エス |
補体因子ｃ３の阻害剤及びそれらの医学的使用
|
|
CA3193488A1
(en)
|
2020-09-23 |
2022-03-31 |
Jason Allan Wiles |
Pharmaceutical compounds for the treatment of complement mediated disorders
|
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
|
JP2024535850A
(ja)
|
2021-09-17 |
2024-10-02 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
|
|
AR127477A1
(es)
|
2021-10-29 |
2024-01-31 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS
|
|
CN114605495A
(zh)
*
|
2022-04-20 |
2022-06-10 |
广州市乾相生物科技有限公司 |
一种乳四肽的合成方法
|
|
WO2025176843A1
(en)
|
2024-02-21 |
2025-08-28 |
Ags Therapeutics Sas |
Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
|
|
WO2025229200A1
(en)
|
2024-05-03 |
2025-11-06 |
Bachem Holding Ag |
Manufacture of disulfide bonded peptides
|
|
US20250361273A1
(en)
*
|
2024-05-24 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions
|
|
WO2026083442A1
(en)
|
2024-10-15 |
2026-04-23 |
Mylan Laboratories Limited |
Process for the preparation of pegcetacoplan and its purification using chromatography
|
|
CN119176856B
(zh)
*
|
2024-11-22 |
2025-03-18 |
杭州诺泰诺和生物医药科技有限公司 |
Pegcetacoplan的制备方法
|
|
US20260234189A1
(en)
|
2025-01-24 |
2026-08-13 |
Boehringer Ingelheim International Gmbh |
Novel and stable compstatin analogues
|